Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 821 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid Plaque Clear all
Completed Phase 3 Interventional Results available

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

NCT06039189
View directory record Official record
Conditions
Moderate Plaque Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
45
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of AA4500 in Men With Peyronie's Disease

NCT01243411
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
secukinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2Phase 3 Interventional Results available

SPECTACL: SPECTroscopic Assessment of Coronary Lipid

NCT00330928
View directory record Official record
Conditions
Angina Pectoris, Angina, Unstable, Myocardial Infarction
Interventions
Near Infrared Spectroscopy (NIRS) Imaging, intravascular ultrasound (IVUS)
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

NCT03764475
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational

Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

NCT03899844
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia
Interventions
Blood collection, PiB PET/MRI, and cognitive testing
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,122 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

NCT02932878
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)

NCT02366689
View directory record Official record
Conditions
Dental Plaque, Gingivitis
Interventions
Triclosan/fluoride toothpaste, stannous fluoride toothpaste, fluoride only toothpaste, Cetylpyridinium chloride mouthwash, Fluoride only mouthwash
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cedar Knolls, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339
View directory record Official record
Conditions
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

NCT01714544
View directory record Official record
Conditions
Psoriasis
Interventions
Cloderm Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 3, 2026, 10:25 AM EDT
Recruiting Phase 1 Interventional

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

NCT05642182
View directory record Official record
Conditions
Psoriasis
Interventions
SFA002
Drug
Lead sponsor
SFA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301
View directory record Official record
Conditions
Psoriasis
Interventions
XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

NCT02239666
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
NIS
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 3, 2026, 10:25 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

NCT01877421
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W, 10 mg KSL-W, 20 mg KSL-W, 30 mg KSL-W, 50 mg KSL-W, 75 mg KSL-W, 100 mg KSL-W, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 3, 2026, 10:25 AM EDT